On July 24, Bristol-Myers Entered Agreement With AstraZeneca To Settle All Outstanding Claims In CTLA-4 Litigation, Two PD-l1 Antibody Litigations; Litigation Settlement, AstraZeneca Parties To Pay Aggregate Of $560M To Co In 4 Payments Through Sept 2026
Portfolio Pulse from Happy Mohamed
Bristol-Myers Squibb (BMY) has entered into an agreement with AstraZeneca (AZN) to settle all outstanding claims in CTLA-4 and two PD-l1 antibody litigations. As part of the settlement, AstraZeneca will pay an aggregate of $560M to Bristol-Myers in four payments through September 2026.
July 27, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca will pay $560M to Bristol-Myers Squibb as part of a litigation settlement. This could potentially impact the company's financial position.
The settlement will result in a significant outflow of cash from AstraZeneca, which could impact its balance sheet. This could potentially have a negative impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Bristol-Myers Squibb will receive $560M from AstraZeneca as part of a litigation settlement. This could potentially improve the company's financial position.
The settlement will result in a significant inflow of cash to Bristol-Myers Squibb, which could be used to strengthen its balance sheet or invest in growth initiatives. This could potentially have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100